Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The company is stepping back in second-line breast cancer.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
First-in-human study listings include EOS-215 and RO7673396.
